In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
The price of Novo Nordisk ADR (NYSE: NVO) closed at $57.12 in the last session, down -3.04% from day before closing price of $58.91. In other words, the price has decreased by -$3.04 from its previous closing price. On the day, 25.67 million shares were traded. NVO stock price reached its highest trading level at $57.83 during the session, while it also had its lowest trading level at $56.3.
Ratios:
We take a closer look at NVO’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 37.52 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 19.24. For the most recent quarter (mrq), Quick Ratio is recorded 0.57 and its Current Ratio is at 0.78. In the meantime, Its Debt-to-Equity ratio is 0.60 whereas as Long-Term Debt/Eq ratio is at 0.52.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on May 30 ’25 when Novo Nordisk A/S bought 921,897 shares for $2.14 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NVO now has a Market Capitalization of 253811539968 and an Enterprise Value of 322442526720. As of this moment, Novo’s Price-to-Earnings (P/E) ratio for their current fiscal year is 16.64, and their Forward P/E ratio for the next fiscal year is 16.24. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.01. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.12 while its Price-to-Book (P/B) ratio in mrq is 9.49. Its current Enterprise Value per Revenue stands at 1.022 whereas that against EBITDA is 1.948.
Stock Price History:
The Beta on a monthly basis for NVO is 0.66, which has changed by -0.25136614 over the last 52 weeks, in comparison to a change of 0.15507638 over the same period for the S&P500. Over the past 52 weeks, NVO has reached a high of $93.80, while it has fallen to a 52-week low of $43.08. The 50-Day Moving Average of the stock is 13.47%, while the 200-Day Moving Average is calculated to be -3.25%.
Shares Statistics:
According to the various share statistics, NVO traded on average about 18.30M shares per day over the past 3-months and 20258580 shares per day over the past 10 days. A total of 3.37B shares are outstanding, with a floating share count of 3.37B. Insiders hold about 0.00% of the company’s shares, while institutions hold 9.04% stake in the company. Shares short for NVO as of 1767139200 were 32384787 with a Short Ratio of 1.77, compared to 1764288000 on 29593438. Therefore, it implies a Short% of Shares Outstanding of 32384787 and a Short% of Float of 0.9599999499999999.
Dividends & Splits
The forward annual dividend rate for NVO is 1.73, which was 11.65 in the trailing 12 months. Against a Trailing Annual Dividend Yield of 0.19775929. The stock’s 5-year Average Dividend Yield is 1.61. The current Payout Ratio is 35.93% for NVO, which recently paid a dividend on 2025-08-18 with an ex-dividend date of 2025-08-18. Stock splits for the company last occurred on 2023-09-20 when the company split stock in a 2:1 ratio.
Earnings Estimates
Currently, 3.0 analysts are dedicated to thoroughly evaluating and rating the performance of Novo Nordisk ADR (NVO) in the stock market.
Analysts are recommending an EPS of between $24.87 and $22.58 for the fiscal current year, implying an average EPS of $23.13. EPS for the following year is $22.38, with 6.0 analysts recommending between $25.85 and $21.28.
Revenue Estimates
According to 8 analysts,. The current quarter’s revenue is expected to be $76.89B. It ranges from a high estimate of $79.3B to a low estimate of $73.62B. As of. The current estimate, Novo Nordisk ADR’s year-ago sales were $85.68BFor the next quarter, 8 analysts are estimating revenue of $74.56B. There is a high estimate of $76.16B for the next quarter, whereas the lowest estimate is $72.97B.
A total of 19 analysts have provided revenue estimates for NVO’s current fiscal year. The highest revenue estimate was $313.33B, while the lowest revenue estimate was $302.49B, resulting in an average revenue estimate of $307.39B. In the same quarter a year ago, actual revenue was $290.4BBased on 21 analysts’ estimates, the company’s revenue will be $304.68B in the next fiscal year. The high estimate is $338.7B and the low estimate is $284.72B.
